Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 14707268
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bcl-2 and apoptosis in chronic lymphocytic leukemia

  2003cited by this paper
• Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more.

  2003cited by this paper
• Aberrant bcl-2 and bax protein expression related to chemotherapy response in neuroblastoma.

  2003cited by this paper
• Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance.

  2003cited by this paper
• Histone Deacetylase Inhibitors in Cancer Therapy

  2003cited by this paper
• Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides.

  2003cited by this paper
• Bryostatin 1 and UCN-01 potentiate 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells through disparate mechanisms.

  2003cited by this paper
• Histone deacetylases as therapeutic targets in hematologic malignancies.

  2002cited by this paper
• The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.

  2002cited by this paper
• The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin

  2002cited by this paper
• Histone deacetylase inhibitors in cancer treatment.

  2002cited by this paper
• Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression

  2002cited by this paper
• Immunobiology of tumor necrosis factor receptor superfamily

  2002cited by this paper
• Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma.

  2002cited by this paper
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily

  2002cited by this paper
• Ubiquitin/Proteasome-dependent Degradation of D-type Cyclins Is Linked to Tumor Necrosis Factor-induced Cell Cycle Arrest*

  2002cited by this paper
• Synergistic induction of apoptosis in human myeloid leukemia cells by phorbol 12-myristate 13-acetate and flavopiridol proceeds via activation of both the intrinsic and tumor necrosis factor-mediated extrinsic cell death pathways.

  2002cited by this paper
• Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA)

  2002cited by this paper
• Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors

  2002cited by this paper
• Histone deacetylase inhibitors in cancer treatment.

  2002cited by this paper
• Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.

  2002cited by this paper
• Apicidin, a Histone Deacetylase Inhibitor, Induces Apoptosis and Fas/Fas Ligand Expression in Human Acute Promyelocytic Leukemia Cells*

  2002cited by this paper
• The Cyclin-Dependent Kinase Inhibitor Butyrolactone Is a Potent Inhibitor of p21WAF1/CIP1 Expression

  2002cited by this paper
• Chemosensitization of T-47D breast carcinoma cells to TRAIL and Fas receptor-induced killing.

  2002cited by this paper
• X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-bi

  2002cited by this paper
• Histone deacetylases and cancer: causes and therapies

  2001cited by this paper
• Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity.

  2001cited by this paper
• Bax and other pro-apoptotic Bcl-2 family "killer-proteins" and their victim the mitochondrion

  2001cited by this paper
• Histone acetylation and disease

  2001cited by this paper
• FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis

  2001cited by this paper
• Histone deacetylase inhibitors as new cancer drugs

  2001cited by this paper
• Butyrate sensitizes human colon cancer cells to TRAIL-mediated apoptosis.

  2001influential reference
• The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

  2001cited by this paper
• The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells.

  2001cited by this paper
• The kiss of death: promises and failures of death receptors and ligands in cancer therapy

  2001cited by this paper
• Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937).

  2001cited by this paper
• The human histone deacetylase family.

  2001cited by this paper
• Histone acetylation and chromatin remodeling.

  2001cited by this paper
• Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.

  2001cited by this paper
• Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.

  2001cited by this paper
• Pioglitazone Inhibits Growth of Carcinoid Cells and Promotes TRAIL-Induced Apoptosis by Induction of p21waf1/cip1

  2001cited by this paper
• Inhibitors of histone deacetylase are potentially effective anticancer agents.

  2001cited by this paper
• Failure of Bcl‐2 to block cytochrome c redistribution during TRAIL‐induced apoptosis

  2000cited by this paper
• Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells.

  2000influential reference
• Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression.

  2000cited by this paper
• Intracellular mechanisms of TRAIL and its role in cancer therapy.

  2000influential reference
• Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.

  2000cited by this paper
• Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease

  2000cited by this paper
• Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity.

  2000cited by this paper
• Caspase 3-mediated Cleavage of p21 WAF1/CIP1 Associated with the Cyclin A-Cyclin-dependent Kinase 2 Complex Is a Prerequisite for Apoptosis in SK-HEP-1 Cells*

  2000cited by this paper
• p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4.

  2000cited by this paper
• Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies

  2000influential reference
• Histone deacetylases, transcriptional control, and cancer

  2000cited by this paper
• Potentiation of 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01).

  2000cited by this paper
• Increased Expression of Death Receptors 4 and 5 Synergizes the Apoptosis Response to Combined Treatment with Etoposide and TRAIL

  2000cited by this paper
• Potentiation of 1-β- d-arabinofuranosylcytosine-mediated mitochondrial damage and apoptosis in human leukemia cells (U937) overexpressing Bcl-2 by the kinase inhibitor 7-hydroxystaurosporine (UCN-01) ∗ ∗ Portions of this work have been reported in preliminary form at the Meeting for the American Ass

  2000cited by this paper
• Mitochondrial control of cell death

  2000cited by this paper
• Caspase 3 inactivation to suppress Fas-mediated apoptosis: identification of binding domain with p21 and ILP and inactivation machinery by p21

  1999cited by this paper
• Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

  1999cited by this paper
• Caspase-3-dependent Cleavage of Bcl-2 Promotes Release of Cytochrome c *

  1999cited by this paper
• IAP family proteins--suppressors of apoptosis.

  1999cited by this paper
• Apoptosis-induced by TRAIL AND TNF-alpha in human multiple myeloma cells is not blocked by BCL-2.

  1999cited by this paper
• Sodium butyrate induces G2 arrest in the human breast cancer cells MDA-MB-231 and renders them competent for DNA rereplication.

  1999cited by this paper
• Apoptosis inhibitory activity of cytoplasmic p21Cip1/WAF1 in monocytic differentiation

  1999influential reference
• The retinoblastoma gene family in differentiation and development

  1999cited by this paper
• Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-beta-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis.

  1999cited by this paper
• Distinct Caspase Cascades Are Initiated in Receptor-mediated and Chemical-induced Apoptosis*

  1999cited by this paper
• Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases

  1999cited by this paper
• Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death*

  1999cited by this paper
• Safety and antitumor activity of recombinant soluble Apo2 ligand.

  1999cited by this paper
• The inhibitors of apoptosis (IAPs) and their emerging role in cancer

  1998cited by this paper
• Regulation of cell proliferation by the E2F transcription factors.

  1998cited by this paper
• The Bcl-2 protein family: arbiters of cell survival.

  1998cited by this paper
• Cleavage of CDK Inhibitor p21Cip1/Waf1 by Caspases Is an Early Event during DNA Damage-induced Apoptosis*

  1998cited by this paper
• Resistance to Fas-mediated apoptosis: activation of Caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP

  1998cited by this paper
• Cleavage of p21Cip1/Waf1 and p27Kip1 mediates apoptosis in endothelial cells through activation of Cdk2: role of a caspase cascade.

  1998cited by this paper
• Butyrate-induced G1 arrest results from p21-independent disruption of retinoblastoma protein-mediated signals.

  1998cited by this paper
• Conversion of Bcl-2 to a Bax-like death effector by caspases.

  1997cited by this paper
• FLICE is activated by association with the CD95 death‐inducing signaling complex (DISC)

  1997cited by this paper
• TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB.

  1997cited by this paper
• An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

  1997cited by this paper
• Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.

  1997cited by this paper
• Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors

  1997cited by this paper
• Inhibition of death receptor signals by cellular FLIP

  1997cited by this paper
• Mitochondrial permeability transition is a central coordinating event of apoptosis

  1996cited by this paper
• Induction of Apoptosis by Apo-2 Ligand, a New Member of the Tumor Necrosis Factor Cytokine Family*

  1996cited by this paper
• Induction of Apoptosis and Potentiation of Ceramide-mediated Cytotoxicity by Sphingoid Bases in Human Myeloid Leukemia Cells (*)

  1996cited by this paper
• FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis.

  1995cited by this paper
• Identification and characterization of a new member of the TNF family that induces apoptosis.

  1995cited by this paper
• Butyrate production from dietary fibre and protection against large bowel cancer in a rat model.

  1993cited by this paper
• Enforced expression of the c-myc oncogene inhibits cell differentiation by precluding entry into a distinct predifferentiation state in G0/G1

  1988cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984cited by this paper

• Risk of hematologic malignancies in psoriasis and rheumatoid arthritis patients using long term TNF-α inhibitors: a retrospective nationwide study

  2025cites this paper
• Design and synthesis of pyridine-based benzamides as potent HDAC3 inhibitors as an armament against breast cancer with in vivo validation.

  2025cites this paper
• Efficacy and challenges involving combination therapies in CLL.

  2024cites this paper
• Extrinsic apoptosis participates to tail regression during the metamorphosis of the chordate Ciona

  2024cites this paper
• Association between the antioxidant properties of SESN proteins and anti-cancer therapies

  2023cites this paper
• Profiling of Circulating Tumor Cells for Screening of Selective Inhibitors of Tumor‐Initiating Stem‐Like Cells

  2023cites this paper
• Selective inhibition of histone deacetylase 3 by novel hydrazide based small molecules as therapeutic intervention for the treatment of cancer.

  2022cites this paper
• Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

  2022influential citation
• Histone Acetylation Defects in Brain Precursor Cells: A Potential Pathogenic Mechanism Causing Proliferation and Differentiation Dysfunctions in Mitochondrial Aspartate-Glutamate Carrier Isoform 1 Deficiency

  2022cites this paper
• Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells.

  2021cites this paper
• Combination treatment with VPA and MSCs-TRAIL could increase anti-tumor effects against intracranial glioma

  2021cites this paper
• Effect of 5'-fluoro-2'-deoxycytidine and sodium butyrate on the genes of the intrinsic apoptotic pathway, p21, p53, cell viability, and apoptosis in human hepatocellular carcinoma cell lines

  2021cites this paper
• Quantitative Proteomic Approach Reveals Altered Metabolic Pathways in Response to the Inhibition of Lysine Deacetylases in A549 Cells under Normoxia and Hypoxia

  2021cites this paper
• HDAC6 Inhibition Extinguishes Autophagy in Cancer: Recent Insights

  2021cites this paper
• Effects of trichostatin A on the intrinsic and extrinsic apoptotic pathway, cell viability, and apoptosis induction in hepatocellular carcinoma cell lines

  2021cites this paper
• 8a, a New Acridine Antiproliferative and Pro-Apoptotic Agent Targeting HDAC1/DNMT1

  2021cites this paper
• CDKN1A Gene Expression in Two Multiple Myeloma Cell Lines With Different P53 Functionality

  2020cites this paper
• Novel regulator role of CIL-102 in the epigenetic modification of TNFR1/TRAIL to induce cell apoptosis in human gastric cancer.

  2020cites this paper
• Histone Deacetylase Inhibitors in Cancer Therapy.

  2019cites this paper
• p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death

  2019influential citation
• Regulation of HDACi−Triggered Autophagy by the Tumor Suppressor Protein p53

  2019cites this paper
• The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

  2019cites this paper
• Hepatitis C Virus Core Protein Enhances Natural Killer Cell Depletion of Plasmacytoid Dendritic Cells

  2019cites this paper
• Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53

  2018influential citation
• HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.

  2018cites this paper
• p53-Mediated Molecular Control of Autophagy in Tumor Cells

  2018cites this paper
• Resveratrol Induces Mitochondrial Apoptosis and Inhibits Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells

  2018cites this paper
• TNF-related apoptosis-inducing ligand (TRAIL) as the potential therapeutic target in hematological malignancies.

  2018cites this paper
• Pre-clinical assessment of the co-operative effects of Trastuzumab and Panobinostat in HER2 overexpressing breast cancer

  2018cites this paper
• Window-of-Opportunity Study of Valproic Acid in Breast Cancer Testing a Gene Expression Biomarker

  2017cites this paper
• 2 Resistance to Apoptosis in Cancer Therapy

  2017cites this paper
• Resveratrol Impairs Glioma Stem Cells Proliferation and Motility by Modulating the Wnt Signaling Pathway

  2017cites this paper
• Stem Cell Regulation by Death Ligands and Their Use in Cell Therapy

  2017cites this paper
• Enhancement of death receptor-mediated apoptosis in multiple myeloma cells

  2017influential citation
• Histone deacetylase inhibitors vorinostat and panobinostat induce G1 cell cycle arrest and apoptosis in multidrug resistant sarcoma cell lines

  2017cites this paper
• ATF3 Repression of BCL-XL Determines Apoptotic Sensitivity to HDAC Inhibitors across Tumor Types

  2017cites this paper
• Histone Deacetylase Inhibitor-Induced Autophagy in Tumor Cells: Implications for p53

  2017cites this paper
• Radioresistant Sf9 insect cells readily undergo an intrinsic mode of apoptosis in response to histone deacetylase (HDAC) inhibition

  2017cites this paper
• SAHA‐induced TRAIL‐sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture

  2017cites this paper
• ATF 3 repression of BCL-X L determines apoptotic sensitivity to HDAC inhibitors across tumour types

  2017cites this paper
• An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts

  2016cites this paper
• Molecular mechanism leading to SAHA-induced autophagy in tumor cells: evidence for a p53-dependent pathway

  2016cites this paper
• Trichostatin A Enhances the Apoptotic Potential of Palladium Nanoparticles in Human Cervical Cancer Cells

  2016cites this paper
• Can post-transcription modifiers change the course of prostate cancer?

  2016cites this paper
• Effects of Sodium Butyrate, a Histone Deacetylase Inhibitor, on TRAIL-mediated Apoptosis in Human Bladder Cancer Cells

  2016cites this paper
• How do tumor cells respond to HDAC inhibition?

  2016cites this paper
• Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma

  2016cites this paper
• Targeting Histone Deacetylases in Melanoma and T-cells to Improve Cancer Immunotherapy

  2016cites this paper
• The Therapeutic Potential of AN-7, a Novel Histone Deacetylase Inhibitor, for Treatment of Mycosis Fungoides/Sezary Syndrome Alone or with Doxorubicin

  2016cites this paper
• TRAIL-based tumor sensitizing galactoxyloglucan, a novel entity for targeting apoptotic machinery.

  2015cites this paper
• Targeting Histone Deacetylases in Diseases: Where Are We?

  2015cites this paper
• Therapeutic applications of TRAIL receptor agonists in cancer and beyond.

  2015cites this paper
• Cinnamomum cassia Suppresses Caspase-9 through Stimulation of AKT1 in MCF-7 Cells but Not in MDA-MB-231 Cells

  2015cites this paper
• Inhibition of myeloid cell leukemia‐1: Association with sorafenib‐induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft

  2015cites this paper
• Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways

  2015cites this paper
• Anticancer potential of the histone deacetylase inhibitor-like effects of flavones, a subclass of polyphenolic compounds: a review

  2015cites this paper
• Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives.

  2015cites this paper
• Role of endogenous retrovirus promoter activity in tumor suppression

  2015cites this paper
• In vitro anticancer drug test: A new method emerges from the model of glioma stem cells

  2014cites this paper
• Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo.

  2014cites this paper
• Small molecules, big effects: the role of microRNAs in regulation of cardiomyocyte death

  2014cites this paper
• SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells

  2014cites this paper
• Novel thalidomide analogs: Anti-angiogenic and apoptotic effects on Hep-G2 and MCF-7 cancer cell lines

  2014cites this paper
• RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells

  2014cites this paper
• Cytostatic and apoptotic effects of DNMT and HDAC inhibitors in endometrial cancer cells.

  2014cites this paper
• Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo

  2014cites this paper
• Histone deacetylase inhibitors and cell death

  2014cites this paper
• Metabolic Effects of Known and Novel HDAC and SIRT Inhibitors in Glioblastomas Independently or Combined with Temozolomide

  2014cites this paper
• Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic pathways in cancer immunosurveillance: molecular mechanisms and prospects for therapy

  2014cites this paper
• inhibitor, in adults with refractory and relapsed acute leukemias Phase 1 and pharmacologic study of MS-275, a histone deacetylase

  2013cites this paper
• ABT-737 accelerates butyrate-induced death of HL-60 cells. Involvement of mitochondrial apoptosis pathway.

  2013cites this paper
• Histone Deacetylases as Targets for Melanoma Immunotherapy

  2013cites this paper
• Original Open Access

  2013cites this paper
• Givinostat and hydroxyurea synergize in vitro to induce apoptosis of cells from JAK2(V617F) myeloproliferative neoplasm patients.

  2013cites this paper
• A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

  2013cites this paper
• Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.

  2013cites this paper
• Effects of sodium butyrate on oxidative stress and behavioral changes induced by administration of D-AMPH.

  2013cites this paper
• Elucidating the mechanism of action of selective histone deacetylase inhibitors in cancer

  2013cites this paper
• Susceptibility of hepatoma-derived cells to histone deacetylase inhibitors is associated with ID2 expression

  2013cites this paper
• Beta Actin Antibody Review and FAQs

  2013cites this paper
• TRAIL-based therapeutic approaches for the treatment of pediatric malignancies.

  2013cites this paper
• Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma

  2013cites this paper
• HDAC inhibitors: applications in oncology and beyond

  2013cites this paper
• Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities

  2013cites this paper
• Analyzing Gene Expression Profile in K562 Cells Exposed to Sodium Valproate Using Microarray Combined with the Connectivity Map Database

  2012cites this paper
• Histone deacetylase inhibitors and rational combination therapies.

  2012cites this paper
• Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death

  2012cites this paper
• Cyclic Adenosine Monophosphate (cAMP)-Induced Histone Hyperacetylation Contributes to its Antiproliferative and Differentiation-Inducing Activities

  2012cites this paper
• Dietary bioactive compounds as histone deacetylase inhibitor for cancer prevention

  2012cites this paper
• In vitro evaluation of the Aurora kinase inhibitor VX-680 for Hepatoblastoma

  2012cites this paper
• Amurensin G, a novel SIRT1 inhibitor, sensitizes TRAIL-resistant human leukemic K562 cells to TRAIL-induced apoptosis.

  2012cites this paper
• Butyrate-induced GPR41 activation inhibits histone acetylation and cell growth.

  2012cites this paper
• Modulation of apoptosis and signalling in cancer cells after treatment with epigenetic modulators

  2012cites this paper
• Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy

  2012cites this paper
• HDAC inhibitor‐based therapies: Can we interpret the code?

  2012cites this paper
• Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma

  2012cites this paper
• Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis.

  2012cites this paper
• Intrinsic and extrinsic apoptotic pathway signaling as determinants of histone deacetylase inhibitor antitumor activity.

  2012cites this paper
• Loading Controls for Western Blots

  2012cites this paper
• Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation

  2012influential citation